Xylem (XYL) EVP Meredith Emmerich granted options and RSU shares

Rhea-AI Filing Summary

Xylem Inc. executive Meredith Emmerich received new equity awards. On March 2, 2026, Emmerich was granted 5,739 non-qualified stock options with an exercise price of $128.98 per share and 1,610 shares of common stock as a restricted stock unit award.

Both the options and restricted stock units were granted under the Xylem 2011 Omnibus Incentive Plan and are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029. The filing also notes additional common shares from dividend reinvestment.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Emmerich Meredith

Role EVP & Pres, AW

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Options (Right to Buy)	5,739	$128.98	$740K
Grant/Award	Common Stock	1,610	$0.00	--

Holdings After Transaction: Non-Qualified Stock Options (Right to Buy) — 5,739 shares (Direct); Common Stock — 5,605 shares (Direct)

Footnotes (1)

1. Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 1, 2027, March 1, 2028 and March 1, 2029. Includes additional shares due to dividend reinvestment. Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Emmerich Meredith

(Last) (First) (Middle)

C/O XYLEM INC.

301 WATER STREET SE

(Street)

WASHINGTON DC 20003

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xylem Inc. [ XYL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Pres, AW

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		A		1,610(1)	A	$0	5,605(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Options (Right to Buy)	$128.98	03/02/2026		A		5,739		(3)	03/02/2036	Common Stock	5,739	$128.98	5,739	D

Explanation of Responses:

1. Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 1, 2027, March 1, 2028 and March 1, 2029.

2. Includes additional shares due to dividend reinvestment.

3. Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.

	/s/ Mike Nazario, by power of attorney for Meredith Emmerich	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Xylem (XYL) EVP Meredith Emmerich receive?

Meredith Emmerich received 5,739 non-qualified stock options and 1,610 shares of common stock as a restricted stock unit grant. Both awards were issued under the Xylem 2011 Omnibus Incentive Plan and increase her direct equity exposure to the company.

What are the vesting dates for Meredith Emmerich’s new Xylem (XYL) awards?

Both the restricted stock units and the non-qualified stock options vest in three equal installments. They are scheduled to vest on March 1, 2027, March 1, 2028, and March 1, 2029, aligning long-term incentives with multi-year performance and retention goals.

What is the exercise price of Meredith Emmerich’s new Xylem (XYL) stock options?

The non-qualified stock options granted to Meredith Emmerich carry an exercise price of $128.98 per share. This price is the amount she would need to pay per share to exercise the options once they vest according to the disclosed schedule.

Were Meredith Emmerich’s Xylem (XYL) common shares in this Form 4 an open-market purchase?

The 1,610 common shares were reported as a grant or award at a price of $0.00 per share, not an open-market purchase. They reflect a restricted stock unit award under the company’s 2011 Omnibus Incentive Plan, with vesting over three future dates.

What plan governs the new equity grants to Xylem (XYL) EVP Meredith Emmerich?

Both the restricted stock units and the non-qualified stock options were granted under the Xylem 2011 Omnibus Incentive Plan, as amended and restated on February 24, 2016. This plan provides the framework for equity-based compensation to company executives and employees.

Does the Xylem (XYL) filing mention dividend reinvestment for Meredith Emmerich’s holdings?

Yes. The filing notes that her reported common stock holdings include additional shares due to dividend reinvestment. This means cash dividends on existing shares were automatically used to acquire incremental shares, increasing her total direct common stock position over time.